Abstract-Robo4, a member of the roundabout family, is expressed exclusively in endothelial cells and has been implicated in endothelial cell migration and angiogenesis. Here we report the cloning and characterization of the human Robo4 promoter. The 3-kb 5Ј-flanking region directs endothelial cell-specific expression in vitro. Deletion and mutation analyses revealed the functional importance of two 12-bp palindromic DNA sequences at Ϫ2528 and Ϫ2941, 2 SP1 consensus motifs at Ϫ42 and Ϫ153, and an ETS consensus motif at Ϫ119. In electrophoretic mobility shift assays using supershifting antibodies, the SP1 motifs bound SP1 protein, whereas the ETS site bound a heterodimeric member of the ETS family, GA binding protein (GABP). These DNA-protein interactions were confirmed by chromatin immunoprecipitation assays. Transfection of primary human endothelial cells with small interfering RNA against GABP and SP1 resulted in a significant (Ϸ50%) reduction in endogenous Robo4 mRNA expression. The 3-kb Robo4 promoter was coupled to LacZ, and the resulting cassette was introduced into the Hprt locus of mice by homologous recombination.
was performed using FuGENE 6 reagent (Roche Molecular Biochemicals, Mannheim, Germany). Nuclear extracts were prepared from HCAECs using Nuclear Extract Kit (Active Motif, Carlsbad, Calif) according to the instructions of the manufacturer. Chromatin immunoprecipitation (ChIP) assays were performed using a Chromatin Immunoprecipitation Assay Kit (Upstate, Lake Placid, NY) according to the instructions of the manufacturer. Immunoprecipitated genomic DNA fragments were quantified by real-time PCR using the primers to amplify the Robo4 proximal promoter region. Hprt-targeted mice were generated as described previously. 11 The generation of the Robo4-lacZ knock-in mouse is detailed in the online data supplement. Expression level of Robo4, CD31, vascular endothelial (VE)-cadherin, and LacZ from mouse tissues and or cultured cells was measured by real-time PCR. All animal experiments were performed according to protocols approved by the Institutional Committee for Use and Care of Laboratory Animals.
An expanded Materials and Methods section is available in the online data supplement.
Results

Cloning and Sequence Analysis of the Human Robo4 Gene
Under in vitro conditions, endogenous Robo4 was expressed at high levels in primary human endothelial cells, but not HCASmCs or HEK293 cells (please see Figure I in the online data supplement). 5Ј Rapid amplification of cDNA ends revealed 2 common transcriptional start sites (supplemental Figure II) . The most frequent transcriptional start site is designated as base pair number ϩ1. The sequence of the upstream promoter region of the human Robo4 gene was determined ( Figure 1 ). The promoter lacks a TATA box. The upstream region includes unique long direct-repeat sequences and 12-bp and 26-bp palindromic sequences ( Figure 1A ). The sequence between Ϫ285 and ϩ40 is 80% conserved between mouse and human and 76% conserved between rat and human ( Figure 1B ). Among the consensus binding sites that are conserved among all 3 species in the 300-bp proximal promoter are ETS and 2 SP1 motifs (discussed below).
Functional Analysis of the Human Robo4 Promoter in Cultured Cells
To compare the activity of the Robo4 promoter with that of other endothelial cell-specific promoters, HUVECs and/or HCAECs were transiently transfected with pGL3 containing the upstream promoter regions of intercellular adhesion molecule-2 (0.37 kb), E-selectin (3 kb), P-selectin (3 kb), ephrinB2 (2.8 kb), Flt-1 (1.4 kb), Robo4 (3 kb) (termed pGL3-Robo4), Tie1 (0.8 kb), or Tie2 (0.72 kb). The Robo4 promoter demonstrated higher activity compared with promoters for intercellular adhesion molecule-2, P-selectin, E-selectin, ephrinB2, Flt-1, and Tie2 and similar activity to the Tie1 promoter (Figure 2A shows HCAECs). To determine whether the Robo4 promoter contains information for endo- thelial-specific expression in vitro, transient transfection assays were also performed in HEK293, HepG2 and U937 cells. As shown in Figure 2B , Robo4 promoter activity was significantly higher in HCAECs compared with HEK293 cells (5-fold), HepG2 cells (29-fold), and U937 cells (18-fold) . Together, these findings suggest that the 3-kb upstream promoter of human Robo4 directs high-level cell typerestricted expression in vitro.
To delineate the functional elements within the upstream promoter region, a series of deletion and mutant promoter fragments were fused to the luciferase reporter gene in pGL3, and the resulting constructs were transiently transfected into HCAECs. Sequential 5Ј deletions resulted in stepwise reduction of promoter activity, with Del1 (Ϫ2450) demonstrating 55%, Del2 (Ϫ1635) demonstrating 44%, Del3 (Ϫ1173) demonstrating 32%, Del4 (Ϫ930) demonstrating 25%, and Del5 (Ϫ329) demonstrating 15% of wild-type level ( Figure  3A) . Deletion of sequences between Ϫ329 and Ϫ228 (Del6) resulted in a slight increase in activity (29%), suggesting the presence of a repressor in that region.
To further delineate the enhancing region between Ϫ2450 and Ϫ3000, additional 5Ј deletions were generated and assayed for luciferase activity. As shown in Figure 3B , Del1-1 (Ϫ2867), Del1-2 (Ϫ2745), Del1-3 (Ϫ2644), and Del1-4 (Ϫ2550) demonstrated activity comparable to the full length 3-kb promoter. The Del1-5 promoter, containing a 2515 bp 5Ј-flanking sequence, resulted in a significant (70%) decrease in activity, whereas further deletions had no such effect. These data suggest that a 35-bp DNA region between Ϫ2550 and Ϫ2515 possesses enhancing activity. This region (which we term the Robo4 enhancer element 1 [REn1]) contains consensus binding sites for nuclear factor-B, nuclear factor of activated T cells (NF-AT), SP1, glucocorticoid receptor, and activator protein 2␥. However, single mutations of these motifs in the context of the 3-kb promoter failed to alter luciferase activity ( Figure 3C ). To further address the role of this region in mediating expression of Robo4, the REn1 was removed from the full-length promoter, inverted, or replaced with 2 different heterologous sequences. As shown in Figure 3D , none of these manipulations strongly affected promoter activity.
Based on these findings, we inferred that additional upstream DNA sequences between Ϫ3000 and Ϫ2551 must compensate for promoter activity in the absence of REn1. To test this hypothesis, 6 new internal-deletion constructs were generated in which the REn1 and progressive lengths of 5Ј sequence were removed from the full-length promoter. As shown in Figure 3E , there was little change in promoter activity with deletions of 100, 200, 300, and 400 bp. However, deletions of 435 bp (Del 435bp) or 465 bp (Del 465bp) resulted in 80% and 70% reduction in promoter activity, respectively, similar to that observed with Del1-5 (the same construct used in Figure 3B ). These data support the existence of a second enhancer between Ϫ2950 and Ϫ2916 (which we term REn2) ( Figure 3F ).
To confirm the dual role for REn1 and REn2 in mediating Robo4 promoter activity, we generated new deletion constructs. Single deletions of REn1 or REn2 resulted in a 15% and 36% reduction in promoter activity, respectively, whereas a double deletion of REn1 and REn2 resulted in 42% decrease in activity ( Figure 3G ). Interestingly, REn1 and REn2 contain 12-bp palindromic DNA sequences (5ЈCA-GAGCCCAGA in REn1; 5ЈTCTGGGCTCTG in REn2) (Figure 3F ). To determine whether these sequences were responsible for the enhancing activity of REn1 and REn2, we deleted the two 12-bp elements from the full-length promoter ( Figure 3G ). The resulting construct demonstrated a 56% reduction in promoter activity, similar to that observed with Del1-5. Taken together, these data support a role for the 12-bp palindromic sequences in mediating Robo4 promoter activity.
We next focused on the proximal region of the human Robo4 promoter because the sequence of the immediate upstream 300-bp region is highly conserved between species, and because the upstream 600-bp region contains putative binding motifs for ETS, SP1, TAL1, E2A, GATA, and nuclear factor-B ( Figure 3H ). A candidate ETS binding site located at Ϫ119 is identical to the known consensus sequence for ETS-1 and ETS-2. This element was designated ETS(1) to distinguish it from other ETS motifs in the promoter. The above sites were mutated alone or in combination (5 Mut and SP1 [1, 2] ) in the context of the 3-kb Robo4 promoter, and the resulting mutants were assayed for activity in transient transfection assays. As shown in Figure 3H , a single mutation of the Ϫ119 ETS(1), Ϫ153 SP1(1), or Ϫ42 SP1(2) site resulted in a 90%, 40%, or 50% reduction in promoter activity, respectively, whereas mutations of the other sites had no significant effect. A double mutation of the SP1 sites (SP1 [1, 2] ) resulted in a 65% reduction in promoter activity.
These findings suggest that the ETS(1), SP1(1), and SP1(2) sites are critical determinants of Robo4 promoter activity.
SP1 Binds to the Human Robo4 Promoter and Induces Promoter Activity
To investigate whether SP1 binds to the SP1(1) and SP1 (2) sites, electrophoretic mobility shift assay (EMSA) was performed. Incubation of a radiolabeled probe spanning the Ϫ153 SP1 site with nuclear extract from HCAECs resulted in a strong DNA-protein complex ( Figure 4A , lane 2). The Robo4 promoter fragments that contained progressive deletions of the 5Ј end were ligated into pGL3, and the resulting constructs were transiently transfected into HCAECs. The deletion constructs are numbered on the left relative to the transcriptional start site. C, Mutations were introduced into pGL3-Robo4 at the indicated sites, and the resulting constructs were transiently transfected into HCAECs. D, The derivative REn1 constructs were prepared by deleting, inverting, or replacing (with 2 heterologous sequences) REn1. The resulting constructs were transiently transfected into HCAECs. E, Internal deletions (REn1: 100, 200, 300, 400, 435, 465 bp) were introduced into pGL3-Robo4. The resulting constructs were transiently transfected in to HCAECs. F, The 12-bp palindromic sequences in REn1 and REn2. Boxed sequence and small arrows indicate 5-bp direct and inverted repeat sequences. G, Deletions were introduced into pGL3-Robo4 at either REn1 or REn2, both REn1 and REn2, or both 12-bp palindromic sequences in REn1 and REn2. The resulting constructs were transiently transfected into HCAECs. H, Mutations were introduced into pGL3-Robo4 at the indicated sites, and the resulting constructs were transiently transfected into HCAECs. Luciferase light units are corrected both for transfection efficiency and relative luciferase activities are indicated by comparing with wild-type Robo4 promoter activity (100%). The data represent meansϮSE of at least 9 replicates. *PϽ0.05 between Robo4 WT and Robo4 mutant promoters.
complex was inhibited by addition of cold wild-type SP1 competitor, but not a mutant SP1 competitor ( Figure 4A , lanes 3 to 6). Preincubation with anti-SP1 antibody resulted in a partial supershift of the specific DNA-protein complex, whereas control antibody had no such effect ( Figure 4A 4B). To determine whether SP1 transactivates the Robo4 promoter through these 2 SP1 sites, cotransfection assays were performed in HEK293 cells using an SP1 expression vector. Overexpression of SP1 resulted in significant (8-fold) induction of Robo4 promoter activity ( Figure 4C) . A single mutation of SP1(1) or SP1(2) reduced the promoter activity to 6.5-or 5.5-fold, respectively. A double mutation of the Ϫ42 and Ϫ153 SP1 motifs (SP1[1,2] ) led to a further reduction in activity (4-fold). Taken together, these data suggest that SP1 regulates the Robo4 promoter activity through both the Ϫ42 and Ϫ153 SP1 sites.
GABP Binds to the Human Robo4 Promoter and Induces Promoter Activity
To identify the factor that binds to the Ϫ119 ETS(1) motif, EMSA was performed as described above using a probe that 1 and 4) or presence of in vitro-translated ETS-1 protein (lanes 2, 3 and 5). As a negative control, in vitro-translated protein from an empty vector was added (lanes 1 and 4) . Antibody to ETS-1 was added in lane 3. F, EMSA was performed with 32 P-labeled ETS probe in the absence (lane 1) or presence of nuclear extract from HCAECs (lanes 2 to 7). In supershift assays, nuclear extracts were incubated in the presence of antibodies to GABP␣ (lane 3), GABP␤ (lane 4), GABP␤/␥ (lane 5), SP1 (lane 6), or control antibody (lane 7). The arrowhead indicates DNA-SP1 complex; the bracket indicates DNA-GABP complex. NS indicates nonspecific band. G, EMSA was performed with 32 P-labeled ETS probe in the absence (lane 1) or presence of in vitro-translated GABP. Arrows indicate DNA-protein complexes derived from GABP␣, GABP␣ and -␤, or GABP␣ and -␥. H, Cotransfection assay was performed in HEK293 cells using 0.1 g of each GABP expression vector (ϩ) or empty vector (Ϫ) and either wild-type pGL3-Robo4 (WT) or a similar construct containing a mutation of the Ϫ119 ETS site (Mut). The data represent meansϮSE of 6 replicates. *PϽ0.05 between control and GABP␣, GABP␣/␤, GABP␣/␥, GABP␤/␥, GABP␣/␤/␥ or GABP␣/␤/␥ with mutant promoter, respectively; #PϽ0.05 between Robo4 WT and mutant promoter.
contains this site. A strong DNA-protein complex was detected ( Figure 4D , lane 2) and was inhibited by addition of wild-type, but not mutant cold ETS(1) competitor ( Figure 4D,  lanes 3 and 4) . Supershift assays were performed with antibodies to ETS factors that have been previously implicated in endothelial cell gene regulation, including ETS-1, ETS-2, ELF-1, FLI-1, ERG, NERF, and PEA3. None of these antibodies resulted in a supershift or inhibited the specific DNA-protein complex ( Figure 4D , lane 5 shows ETS-1). As a positive control for ETS-1 binding and supershifting activity of the ETS-1 antibody, a radiolabeled probe spanning the consensus ETS-1 binding motif was incubated with recombinant ETS-1. As shown in Figure 4E , ETS-1 protein bound to the classical ETS motif (but not ETS [1] from the Robo4 promoter), and the resulting DNA-protein complex was supershifted by ETS-1 antibody.
Based on the above results, we explored the potential role of another ETS factor that has not been previously described in endothelial cells, namely GA binding protein (GABP). GABP binds as a complex consisting of heterodimers of GABP␣ and GABP␤ or ␥. GABP␥ is an alternative splice form of GABP␤ (see review 12 ). In supershift assays, preincubation with antibodies against GABP␣ or GABP␤/␥ resulted in complete inhibition of the DNA-protein complex ( Figure 4F, lanes 3 and 5) . In contrast, anti-GABP␤ antibody had minimal effect on DNA binding, and anti-SP1 antibody resulted in loss of a more slowly migrating DNA-protein complex ( Figure 4F, lanes 4 and 6) . In vitro translated protein consisting of GABP␣, GABP␣/␤, or GABP␣/␥ resulted in specific DNA-protein complexes compatible with those observed with nuclear extracts ( Figure 4G) .
In cotransfection assays, overexpression of GABP␣, alone or together with GABP␤ or GABP␥, resulted in significant induction of Robo4 promoter activity, whereas GABP␤ or GABP␥ alone had no such effect ( Figure 4H) . Mutation of the ETS(1) site significantly attenuated GABP-mediated transactivation of the promoter ( Figure 4H ). Together, these data suggest that GABP plays an important role in mediating Robo4 expression.
SP1 and GABP Bind to the Endogenous Human Robo4 Promoter in Primary Endothelial Cells
To investigate whether SP1 and GABP bind to the Robo4 proximal region in endothelial cells, ChIP assay was performed. Formalin-fixed genomic DNA-protein complexes from HCAECs and HCASmCs were sheared by sonication ( Figure 5A ). Resulting small DNA-protein complexes were immunoprecipitated with antibodies to SP1, GABP␣, or Egr-1 (control IgG), and the resulting products were used as template in a PCR reaction containing primers specific for the immediate upstream promoter of Robo4. Real-time PCR was used to calculate binding intensities. As shown in Figure 5B , SP1, and GABP␣, but not Egr-1 (control IgG), bound to the proximal promoter region. Similar results were obtained with primary vascular smooth muscle cells ( Figure 5B ). These results demonstrate that SP1 and GABP bind to the Robo4 proximal region in vivo and that this interaction is not specific to endothelial cells.
Small Interfering RNA-Mediated Knockdown of GABP␣ and SP1 Results in Significant Reduction of Endogenous Robo4 mRNA Expression
To determine whether SP1 and GABP␣ play a role in mediating the endogenous expression of Robo4, small interfering RNA (siRNA) against these transcription factors were transfected into HCAECs. As shown in Figure 5C , siRNA Figure 5 . Binding of SP1 and GABP to the proximal region in vivo and siRNAmediated knockdown of SP1 and GABP␣. ChIP assay was performed using HCAECs and HCASmCs. A, The sheared DNA samples were analyzed by 1.7% agarose gel. B, Resulting DNAprotein complexes were immunoprecipitated in the absence or presence of 8 g of antibodies to SP1, GABP␣, or Egr-1 (control IgG). Real-time PCR analysis was performed using the precipitated DNA fragments and primers for Robo4 proximal region, which included the SP1 and ETS(1) site. C, HCAECs were transfected with 100 pmol of siRNA against SP1, GABP␣, or negative control siRNA using Lipofectamine 2000 reagent according to the instructions of the manufacturer. After 48 hours of incubation, total RNAs were prepared by RNeasy RNA extraction kit. Samples were assayed by real-time PCR for expression of SP1, GABP␣, and Robo4.
against SP1 resulted in a 5.3-fold reduction in SP1 and a 1.9-fold reduction of Robo4 expression, whereas siRNA against GABP␣ resulted in 4.9-fold reduction in GABP␣ and 2.2-fold decrease in Robo4.
The Three-Kilobase Human Robo4 Promoter Contains Information for Endothelial-Specific Expression in Mice
To determine whether the Robo4 promoter directs lineagespecific expression in vivo, the 3-kb promoter region was coupled to LacZ. A single copy of the transgenic cassette was targeted to the Hprt locus of mice using homologous recombination as previously described. High percentage chimeric males were bred to wild-type females. Resulting female agouti offspring were bred to generate stable lines and F 2 males were assayed for LacZ expression.
Whole-mount staining of organs (brain, heart, lung, skeletal muscle, aorta, trachea, diaphragm, and esophagus) revealed widespread, although not uniform, ␤-galactosidase activity in the vasculature (Figure 6 ). Tissue sections revealed LacZ staining in the endothelial lining of vessels in all organs examined ( Figure 7B ). Expression was greater in the microvessels compared with macrovessels. In the kidney, ␤-galactosidase activity was highest in the glomeruli. In serial sections, LacZ colocalized with CD31. LacZ was not observed in any other cell type or lineage including peripheral blood cells and bone marrow (supplemental Figure III) .
We compared expression of LacZ mRNA with that of endogenous Robo4 and 2 endothelial markers, CD31 and VE-cadherin, using real-time PCR of adult mouse tissues. As shown in Figure 7C , Robo4 transcripts were detected in all organs, according to the following rank order: lungϾheartϾkidneyϾskeletal muscleϾliverϾspleenϭbrain.
Importantly, LacZ mRNA expression in Hprt-targeted mice followed a similar pattern. To control for vascular density, tissue samples were also assayed for CD31 and VE-cadherin. The pattern of LacZ and Robo4 expression mirrored that of VE-cadherin and CD31 ( Figure 7C) . (In the case of CD31, expression was relatively higher in spleen, presumably owing to positivity in hematopoietic cells.) These data suggest that expression of the transgene mimics that of the endogenous Robo4 gene, which in turn correlates with the degree of vascularization. LacZ expression was also detected in the endothelium of embryos and tumor xenografts (supplemental Figures IV and V) .
As a second strategy for comparing the expression of the Hprt-targeted transgene and the endogenous gene, we knocked LacZ into the endogenous Robo4 locus ( Figure 8A) . Heterozygous F2 adult males demonstrated endothelial cellspecific expression of LacZ in the vasculature ( Figure 8B and 8C). One exception was the brain, where mounts and tissue sections revealed a weak nonvascular distribution in the pia mater (data not shown). Compared with the Hprt locustargeted mice, the LacZ knock-in animals demonstrated lower ␤-galactosidase activity in the vasculature. Moreover, reporter gene expression in the aorta was more restricted to branch orifices and tributaries and was undetectable in the large arteries of the brain. Otherwise, the pattern of expression was similar between the two lines of mice, with predominant staining in the microvascular endothelium.
Discussion
We have cloned and characterized the human Robo4 promoter. Similar to the endogenous Robo4 gene, a 3-kb fragment of the upstream promoter directed high-level lineage-specific expression in cultured endothelial cells. 5Ј- Figure 6 . LacZ staining of whole organs from Hprt-Robo4-lacZ mice. Organs were harvested from F1 female Hprt-targeted mice carrying the Robo4-lacZ transgene or age-matched controls and processed for whole-mount staining with X-gal. Arrowheads indicate strong LacZ staining at branch orifices and tributaries of aorta.
Deletion analyses revealed several positive regulatory regions. Using a series of mutational analyses, EMSA, ChIP, and siRNA-mediated knockdown experiments, we have demonstrated an important role for SP1 and GABP in governing basal expression of Robo4. In addition, we have identified 12-bp palindromic DNA sequences that are important for Robo4 promoter activity in endothelial cells. This DNA sequence does not conform to established cis-regulatory motifs and thus represents a potentially novel regulatory element. The mechanism by which the palindromic sequences mediate Robo4 expression is the focus of ongoing studies.
Members of the ETS family of transcription factors share an evolutionarily conserved DNA-binding domain of 85 aa with a winged-helix-turn-helix configuration. 13 ETS factors bind to GGAA/T core sequences. Consensus ETS binding motifs have been identified within the promoters of several other endothelial cell genes, including Flt-1, Tie1, Tie2, and VE-cadherin. 14 -18 The functional relevance of ETS motifs in mediating endothelial cell gene expression has been demonstrated both in vitro and in vivo. Several ETS factors have been shown to mediate gene expression in endothelial cells, most notably ETS-1, ETS-2, ESE-1, NERF2, and ELF-1. 19 GABP (also known as nuclear respiratory factor [NRF]-2 and adenovirus E4 transcription factor [E4TF]-1) is unique among the ETS family of transcription factors in that it forms multimers, consisting of 2 structurally unrelated subunits: GABP␣ and GABP␤. GABP␣ contains the ETS DNAbinding region, whereas GABP␤ is required for nuclear translocation and transactivation. GABP␤ stabilizes the GABP␣-DNA interaction more than 100-fold. 20 Mammalian GABP is ubiquitously expressed in all tissues and has been implicated in several critical cellular processes including cellular respiration in mitochondria, differentiation, cell cycle, cell survival, and neuromuscular function. 12 Mice that are null for GABP␣ are embryonic lethal and die before implantation. 21 In addition to controlling the expression of housekeeping genes, GABP has been shown to regulate the expression of cell type-specific genes in several distinct lineages, including myeloid cells, lymphocytes, neuromuscular cells, hepatocytes, and mast cells. 12 To our knowledge, this is the first study to demonstrate a role for GABP in promoting the expression of an endothelial cell-specific target gene.
Our data are consistent with the notion that SP1 and GABP are necessary for full basal expression of Robo4 in endothelial cells. They do not prove that these transcription factors mediate cell type-specific gene expression. Indeed, SP1 and GABP are expressed in other cell types, and ChIP assays in vascular smooth muscle cells revealed binding of both transcription factors to the Robo4 promoter in an otherwise nonexpressing cell type. Thus, other mechanisms must be responsible for cell type-specific gene expression. One possibility is that GABP interacts with cell type-specific transcription factors or coactivators to promote cell-specific responses.
Previous studies using standard transgenic mouse assays or Hprt locus targeting have demonstrated that the majority of endothelial-specific promoters direct expression to specific vascular beds (reviewed previously 22 ). In the current study, the Hprt-targeted 3-kb Robo4 promoter directed expression in the embryonic and adult vasculature. Reporter gene expression was restricted to the endothelium. Expression was more prominent in microvessels compared with macrovessels. Even within microvessels, LacZ expression was nonuniform. In real-time PCR analyses, LacZ mRNA expression correlated with expression of endogenous Robo4. Moreover, the expression pattern was similar to that observed when the LacZ reporter gene was knocked into the Robo4 locus. Because the knock-in strategy involved deletion of Robo4 DNA sequences, including potential regulatory elements in the first 3 introns, it is formally possible that the LacZ expression does not precisely reflect the endogenous of the Robo4 gene. That caveat notwithstanding, our data suggest that the 3-kb human Robo4 promoter contains information for near-authentic expression in the endothelium.
Based on its exquisite cell type specificity, and its expression in the neovasculature, the Robo4 gene (and promoter) represents a powerful tool for dissecting the molecular basis of lineage determination and new blood vessel growth. , and exons (E1-10) are indicated. B, Organs were harvested from F1 male heterozygous mice carrying the LacZ gene, or age-matched controls (data not shown), and processed for whole-mount staining with X-gal. Arrowheads indicate strong LacZ staining at branch orifices and tributaries of aorta. C, Serial sections were prepared from organs of Robo4-lacZ knock-in F1 mice and stained with CD31 antibody or X-gal to detect endogenous CD31 or LacZ, respectively. For each organ, low-power images are shown on the top, and high power images on the bottom (scale bars for low and high power images are shown in the bottom right images).
